A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Blood is an easily accessible source of tumor cell free (cf) DNA. Both normal and malignant cells shed DNA into the circulation, and advanced genomics technologies can analyze tumor cfDNA, making blood a source of real-time genomic tumor profiling. For ccRCC patients, peripheral blood will be obtained as part of …
This study has two parts: Part 1 (dose escalation) and Part 2 (dose expansion). The purpose of Part 1 is to determine: What effects, good and/or bad, STRO-002 has on subjects and their disease The highest dose of STRO-002 that can be safely given to subjects using a pre-defined starting …
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
This research study is for those with you have advanced cancer. This research study is designed to learn more about the safety and effectiveness of FS118, an investigations drug given to individuals who have been diagnosed with advanced cancer.
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
Please refer to Protocol Section 3.0 (Study Objectives and Endpoints). Please refer to Protocol Section 3.0 (Study Objectives and Endpoints). Please refer to Protocol Section 3.0 (Study Objectives and Endpoints).
This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30). All subjects must have histologically confirmed World Health Organization (WHO) …
This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment …
This research study is being conducted to determine if a new investigational device (Instylla Hydrogel Embolic system) can be used to treat tumors which have an extensive blood supply. This means that the tumors have many blood vessels feeding them. This product will be used to close blood vessels supplying …